198 related articles for article (PubMed ID: 9013966)
41. Natural killer cells participate in the early defense against Leishmania major infection in mice.
Laskay T; Röllinghoff M; Solbach W
Eur J Immunol; 1993 Sep; 23(9):2237-41. PubMed ID: 8370404
[TBL] [Abstract][Full Text] [Related]
42. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells.
Aseffa A; Gumy A; Launois P; MacDonald HR; Louis JA; Tacchini-Cottier F
J Immunol; 2002 Sep; 169(6):3232-41. PubMed ID: 12218142
[TBL] [Abstract][Full Text] [Related]
43. Genotypically distinct strains of Leishmania major display diverse clinical and immunological patterns in BALB/c mice.
Alimohammadian MH; Darabi H; Ajdary S; Khaze V; Torkabadi E
Infect Genet Evol; 2010 Oct; 10(7):969-75. PubMed ID: 20601170
[TBL] [Abstract][Full Text] [Related]
44. Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility.
Nagase H; Jones KM; Anderson CF; Noben-Trauth N
J Immunol; 2007 Aug; 179(4):2435-44. PubMed ID: 17675505
[TBL] [Abstract][Full Text] [Related]
45. Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice.
Louis JA; Conceiçao-Silva F; Himmelrich H; Tacchini-Cottier F; Launois P
Adv Exp Med Biol; 1998; 452():53-60. PubMed ID: 9889959
[TBL] [Abstract][Full Text] [Related]
46. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge.
Okwor I; Kuriakose S; Uzonna J
Vaccine; 2010 Jul; 28(33):5451-7. PubMed ID: 20558242
[TBL] [Abstract][Full Text] [Related]
47. An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major.
Tacchini-Cottier F; Zweifel C; Belkaid Y; Mukankundiye C; Vasei M; Launois P; Milon G; Louis JA
J Immunol; 2000 Sep; 165(5):2628-36. PubMed ID: 10946291
[TBL] [Abstract][Full Text] [Related]
48. Requirement of SIRPα for protective immunity against Leishmania major.
Morimoto N; Murata Y; Motegi S; Suzue K; Saito Y; Okazawa H; Ohnishi H; Kotani T; Kusakari S; Ishikawa O; Matozaki T
Biochem Biophys Res Commun; 2010 Oct; 401(3):385-9. PubMed ID: 20854790
[TBL] [Abstract][Full Text] [Related]
49. T cells from Leishmania major-susceptible BALB/c mice have a defect in efficiently up-regulating CXCR3 upon activation.
Barbi J; Brombacher F; Satoskar AR
J Immunol; 2008 Oct; 181(7):4613-20. PubMed ID: 18802063
[TBL] [Abstract][Full Text] [Related]
50. KM(+), a lectin from Artocarpus integrifolia, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against Leishmania major antigens, resulting in BALB/c mice resistance to infection.
Panunto-Castelo A; Souza MA; Roque-Barreira MC; Silva JS
Glycobiology; 2001 Dec; 11(12):1035-42. PubMed ID: 11805076
[TBL] [Abstract][Full Text] [Related]
51. IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections.
Leiby DA; Schreiber RD; Nacy CA
Microb Pathog; 1993 Jun; 14(6):495-500. PubMed ID: 8412622
[TBL] [Abstract][Full Text] [Related]
52. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb.
Ferlin WG; von der Weid T; Cottrez F; Ferrick DA; Coffman RL; Howard MC
Eur J Immunol; 1998 Feb; 28(2):525-31. PubMed ID: 9521062
[TBL] [Abstract][Full Text] [Related]
53. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling.
Nishikomori R; Gurunathan S; Nishikomori K; Strober W
J Immunol; 2001 Jun; 166(11):6776-83. PubMed ID: 11359836
[TBL] [Abstract][Full Text] [Related]
54. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease.
Himmelrich H; Launois P; Maillard I; Biedermann T; Tacchini-Cottier F; Locksley RM; Röcken M; Louis JA
J Immunol; 2000 May; 164(9):4819-25. PubMed ID: 10779790
[TBL] [Abstract][Full Text] [Related]
55. Leishmania major: secreted antigens of Leishmania major promastigotes shift the immune response of the C57BL/6 mice toward Th2 in vitro.
Tabatabaee PA; Abolhassani M; Mahdavi M; Nahrevanian H; Azadmanesh K
Exp Parasitol; 2011 Jan; 127(1):46-51. PubMed ID: 20603118
[TBL] [Abstract][Full Text] [Related]
56. Kinetics of cell-mediated immunity developing during the course of Leishmania major infection in 'healer' and 'non-healer' mice: progressive impairment of response to and generation of interleukin-2.
Solbach W; Lohoff M; Streck H; Rohwer P; Röllinghoff M
Immunology; 1987 Nov; 62(3):485-92. PubMed ID: 3499384
[TBL] [Abstract][Full Text] [Related]
57. Subverting lymph node trafficking by treatment with the Mel-14 monoclonal antibody to L-selectin does not prevent an effective host response to Sendai virus.
Hou S; Hyland L; Bradley LM; Watson SR; Doherty PC
J Immunol; 1995 Jul; 155(1):252-8. PubMed ID: 7541416
[TBL] [Abstract][Full Text] [Related]
58. Loss of TNF signaling facilitates the development of a novel Ly-6C(low) macrophage population permissive for Leishmania major infection.
Fromm PD; Kling J; Mack M; Sedgwick JD; Körner H
J Immunol; 2012 Jun; 188(12):6258-66. PubMed ID: 22615203
[TBL] [Abstract][Full Text] [Related]
59. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area.
Rosato A; Zambon A; Macino B; Mandruzzato S; Bronte V; Milan G; Zanovello P; Collavo D
Int J Cancer; 1996 Mar; 65(6):847-51. PubMed ID: 8631602
[TBL] [Abstract][Full Text] [Related]
60. Cell contact-mediated macrophage activation for antileishmanial defense. II. Identification of effector cell phenotype and genetic restriction.
Sypek JP; Panosian CB; Wyler DJ
J Immunol; 1984 Dec; 133(6):3351-7. PubMed ID: 6333458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
